Smoking Cessation in a Blue-Collar Population: Results From and Evidence-Based Pilot Program
(Part of American Journal of Industrial Medicine, Volume 42, Issue 5, 2002)
|
|
American Journal of Industrial Medicine
|
|
|
Funded by:
- Glaxo Wellcome,
Inc.
- Glaxo SmithKline,
Inc.
Keywords:
blue collar •
smoking • smoking cessation • behavioral counseling • pharmacotherapy
• efficacy • costs • benefits • return on investment
Abstract:
Background
Taft Hartley Funds provide group health care coverage for 10 million union
workers as well as their dependents in industries such as construction
and transportation. The adult smoking rate in these populations is estimated
at approximately 40%, therefore, these funds include 9 million adult smokers.
The absence of evidence demonstrating the effectiveness of smoking cessation
programs has kept Taft Hartley Funds from investing in smoking cessation
benefits.
Methods
A prototype for Taft Hartley Funds consistent with the Federal Clinical
Guidelines for Smoking Cessation was designed and implemented in a pilot
demonstration in the Carpenters Health and Security Trust of Western Washington.
Participants chose a 1-call or more intensive 5-call smoking cessation
counseling plan provided by the Group Health Cooperative's Free and Clear
program. Medications were limited to the nicotine patch, nicotine gum,
and Bupropion. Assessment of outcomes was performed by Free and Clear
through a telephone survey 12 months following the enrollment date.
Results
Nine hundred thirty-five smokers participated in the program. This pilot
evaluation covers 325 participants with at least 12 months since enrollment;
75% were male, the average age was 41.4 and 63% had smoked at least one
pack per day for more than 20 years. Sixty-one percent selected 5-Call
Counseling; 39% 1-Call. Seventy-five percent also used smoking cessation
medications: gum, 4%; patch, 32%; Bupropion 21.5%; patch plus Bupropion,
15.7%. The point-prevalence-quit rates were: overall, 27.5%; 1-Call, 25.5%;
and 5-Call, 28.9%. The cost of the program was $1025.28 per smoker who
quit, or $11.78 per full-time equivalent employee covered by the Fund
per year. The compounded savings in reduced lifetime tobacco-related medical
costs for the participants who quit are estimated to be 15 times the cost
of the program, yielding an annual return on investment of 27.6%.
Conclusions
These results strongly suggest that smoking cessation programs can be
effective even in such hard-to-reach populations as itinerant building
trades workers, provided that the program is designed to their needs and
environment. Based on these findings, health plans need to consider whether
they are at risk of violating their fiduciary duties if they fail to offer
smoking cessation benefits. Am. J. Ind. Med. 42:367-377, 2002.
Accepted:
10 July 2002
Digital Object Identifier (DOI): 10.1002/ajim.10129
1 Stoneturn Consultants, Seattle, Washington
2 Carpenters Trust of Western Washington, Seattle, Washington
3 Group Health Cooperative, Center for Health Promotion, Seattle,
Washington
4 GlaxoSmithKline, Inc., Phoenix, Arizona
This paper appears in the eLCOSH website with the permission of the author
and/or copyright holder and may not be reproduced without their consent. eLCOSH is an
information clearinghouse. eLCOSH and its sponsors are not responsible for the accuracy of
information provided on this web site, nor for its use or misuse.
|
|